Genelux Corporation(GNLX)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | Smalling Ralph Head of Regulatory | Sale | -192 | -0.28%67,611 | $2.93 | $563 | View SEC filing | |
| 2026-06-02 | Thomas John Director | Sale | -10,000 | -2.07%472,784 | $2.98 | $29,801 | View SEC filing | |
| 2026-05-12 | Cappello Joseph Chief Technical Officer | Sale | -605 | -0.39%154,549 | $2.97 | $1,799 | View SEC filing | |
| 2026-05-12 | Yu Yong Chief Scientific Officer | Sale | -605 | -0.40%149,706 | $2.97 | $1,798 | View SEC filing | |
| 2026-05-12 | Zindrick Thomas President and CEO | Sale | -2,798 | -0.52%532,051 | $2.94 | $8,226 | View SEC filing | |
| 2026-05-12 | Smalling Ralph Head of Regulatory | Sale | -270 | -0.40%67,803 | $2.98 | $804 | View SEC filing | |
| 2026-03-26 | Smalling Ralph Head of Regulatory | Sale | -585 | -0.85%68,073 | $2.46 | $1,437 | View SEC filing | |
| 2026-03-26 | Cappello Joseph Chief Technical Officer | Sale | -906 | -0.58%155,154 | $2.42 | $2,193 | View SEC filing | |
| 2026-03-26 | Yu Yong SVP, Clinical Development | Sale | -906 | -0.62%144,938 | $2.42 | $2,193 | View SEC filing | |
| 2026-03-26 | Zindrick Thomas President and CEO | Sale | -3,582 | -0.67%534,849 | $2.42 | $8,668 | View SEC filing | |
| 2026-03-03 | Thomas John Director | Sale | -10,000 | -2.03%482,784 | $2.90 | $28,957 | View SEC filing | |
| 2025-12-11 | Zindrick Thomas President and CEO | Sale | -17,182 | -3.09%538,431 | $3.86 | $66,370 | View SEC filing | |
| 2025-12-11 | Yu Yong SVP, Clinical Development | Sale | -4,192 | -2.79%145,844 | $3.82 | $16,032 | View SEC filing | |
| 2025-12-11 | Cappello Joseph Chief Technical Officer | Sale | -3,706 | -2.32%156,060 | $3.88 | $14,361 | View SEC filing | |
| 2025-12-09 | Smalling Ralph Head of Regulatory | Sale | -2,332 | -3.28%68,658 | $3.75 | $8,740 | View SEC filing | |
| 2025-12-02 | Thomas John Director | Sale | -10,000 | -1.99%492,784 | $5.00 | $50,008 | View SEC filing | |
| 2025-05-13 | Ryder Sean General Counsel | Sale | -4,475 | -8.59%47,621 | $2.92 | $13,067 | View SEC filing | |
| 2025-05-13 | Zindrick Thomas President and CEO | Sale | -10,764 | -5.32%191,447 | $2.92 | $31,431 | View SEC filing | |
| 2025-05-13 | Yu Yong VP, Clinical Trial Operations | Sale | -5,579 | -10.48%47,640 | $2.92 | $16,291 | View SEC filing | |
| 2025-05-13 | Cappello Joseph VP, Pharmaceutical Development | Sale | -4,737 | -8.31%52,266 | $2.92 | $13,832 | View SEC filing | |
| 2025-05-13 | Smalling Ralph Head of Regulatory | Sale | -1,259 | -3.50%34,760 | $2.92 | $3,676 | View SEC filing | |
| 2024-12-30 | Tyree James L Director | Sale | -3,460 | -7.03%45,791 | $2.46 | $8,512 | View SEC filing | |
| 2024-12-18 | Zindrick Thomas President and CEO | Sale | -14,315 | -27.70%37,372 | $2.34 | $33,497 | View SEC filing | |
| 2024-12-18 | Zak Lourie S. Chief Financial Officer | Sale | -2,103 | -4.90%40,802 | $2.34 | $4,921 | View SEC filing | |
| 2024-12-18 | Smalling Ralph Head of Regulatory | Sale | -2,510 | -13.33%16,322 | $2.34 | $5,873 | View SEC filing |
1-25 of 85